In her article in Rx Data, Jane Reed, Director Life Science at Linguamatics, discusses the impact of advanced data technologies (artificial intelligence and machine learning) on innovation in drug discovery, development and delivery.
We are now in the fourth industrial revolution (4IR), known to some as the Big Data Revolution. Advances in connectivity and communication, in the digital revolution, bring results such as improved data access and the new-found potential to analyze huge volumes of data. The ability to access these important volumes of varied data and to connect, integrate, query and analyze it is enabling fundamental changes in how we envision drug discovery and delivery in the clinic. Additionally, the pace of these changes is also remarkable; Jane notes a few examples of some genome-based projects and the fast-paced evolution, from the first human chromosome sequenced in 1999; the human genome published in draft in 2001, to the more recent UK 100k Genome project.
According to Jane, the key components for these innovations include data integration and data analysis. To keep up with that rhythm, pharma companies now need to join up genomic data with clinical information and knowledge about particular diseases.